Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05038254 · ClinicalTrials.gov registry record · NA
Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events
A NA study of Clinical Stage IV Gastric Cancer AJCC v8 and Clinical Stage IVA Gastric Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 750
- Enrollment target
- 1
- Study location
NCT05038254: Active NA study of Clinical Stage IV Gastric Cancer AJCC v8 and Clinical Stage IVA Gastric Cancer AJCC v8, sponsored by M.D. Anderson Cancer Center.
NCT05038254 is a NA study of Clinical Stage IV Gastric Cancer AJCC v8 and Clinical Stage IVA Gastric Cancer AJCC v8 that is active but no longer recruiting, run by M.D. Anderson Cancer Center. The registered enrollment target is 750 participants, above the 179-participant average among 17 other Clinical Stage IV Gastric Cancer AJCC v8 trials with a reported enrollment target (319% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05038254, a NA study of Clinical Stage IV Gastric Cancer AJCC v8 and Clinical Stage IVA Gastric Cancer AJCC v8, is active but no longer recruiting, sponsored by M.D. Anderson Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 750 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical trial studies if enhanced outpatient symptom management with telemedicine and remote monitoring can help reduce acute care visit due to chemotherapy-related adverse events. Receiving telemedicine and remote monitoring may help patients have better outcomes (such as fewer avoidable emergency room visits and hospitalizations, better quality of life, fewer symptoms, and fewer treatment delays) than patients who receive usual care.
Primary Outcome
Defined as the proportion of unique oncology patients with emergency room visits or hospital admission over a 3-month period.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- OTHER Best Practice
- PROCEDURE Patient Monitoring
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2021-05-12 |
| Est. Completion | 2026-01-31 |
| Phase | NA |
What the registry record for NCT05038254 still lists
NCT05038254 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 179-participant average among 17 other Clinical Stage IV Gastric Cancer AJCC v8 trials with a reported enrollment target (319% higher).
The record links to 10 conditions, with Clinical Stage IV Gastric Cancer AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT05038254 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05038254 about?
NCT05038254 is a clinical study titled "Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events". This clinical trial studies if enhanced outpatient symptom management with telemedicine and remote monitoring can help reduce acute care visit due to chemotherapy-related adverse events. Receiving telemedicine and remote monitoring may help patients have better outcomes (such as fewer avoidable emer...
What is the current status of trial NCT05038254?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 750 participants. The study started on 2021-05-12. Estimated completion is 2026-01-31.
What conditions does trial NCT05038254 study?
This clinical trial studies the following conditions: Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8.
What interventions are being tested in trial NCT05038254?
The interventions under investigation include: Questionnaire Administration (OTHER), Best Practice (OTHER), Patient Monitoring (PROCEDURE).
Who is sponsoring clinical trial NCT05038254?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05038254 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clinical Stage IV Gastric Cancer AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05038254's enrollment target sits among peer trials
750 2nd of 17 the highest of 17 other Clinical Stage IV Gastric Cancer AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Clinical Stage IV Gastric Cancer AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Intravital Microscopy in Human Solid Tumors
RECRUITING · NA
-
Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer
RECRUITING · NA
-
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
RECRUITING · Phase 1
-
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
RECRUITING · Phase 1
-
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
RECRUITING · Phase 2
-
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI